A Phase 2, Multicenter, Single-Arm Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 10 Aug 2016
At a glance
- Drugs Eribulin (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Eisai Inc
- 10 Jun 2017 Biomarkers information updated
- 18 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Dec 2013 Final results presented at the 36th Annual San Antonio Breast Cancer Symposium.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History